Browsing by Author "Ferhanoğlu, Burhan"
Now showing items 1-9 of 9
-
Complete remission of burkitt lymphoma after surgical excision: A case report
Beköz, Hüseyin Saffet; Kantarcıoğlu, Bülent; Tecimer, Tülay; Üskent, Necdet; Çetiner, Mustafa; Ferhanoğlu, Burhan; Sargın, Deniz (Springer India, 2016)Burkitt lymphoma (BL) is a highly aggressive B cell non-Hodgkin lymphoma that has a high proliferation rate. The prognosis for BL is generally favorable, with cure rate of 75-90 % with modern chemoimmunotherapy regimens. ... -
COVID-19 infection in patients with acute leukemia; Istanbul experience
Büyüktaş, Deram; Acar, Kadir; Sucak, Gülsan; Toptaş, Tayfur; Kapucu, İrem; Beköz, Hüseyin; Erdem, Simge; Nalcacı, Meliha; Atalay, Figen; Akay, Olga Meltem; Ferhanoğlu, Burhan (e-Century Publishing Corp, 2021)Coronavirus disease 2019 (COVID-19) has led to a global pandemic that has also challenged the management of various other life-threatening conditions, such as malignant disorders. In this study, we present the clinical ... -
Early changes of mannose-binding lectin, H-ficolin, and procalcitonin in patients with febrile neutropenia: A prospective observational study
Mutcali Islak, Sibel; Saltoğlu, Neşe; Balkan İnanç, Ilker; Özaras, Reşat; Yemişen, Mücahit; Mete, Bilgül; Tabak, Fehmi; Mert, Ali; Öztürk, Recep; Öngören, Seniz; Başlar, Zafer; Aydın, Yıldız; Ferhanoğlu, Burhan; Soysal, Teoman (Galenos Yayıncılık, 2016)Objective: The significance of mannose-binding lectin (MBL) and H-ficolin deficiency in febrile neutropenic (FN) patients and the correlation of these markers along with consecutive C-reactive protein (CRP) and procalcitonin ... -
Glofitamab in relapsed/refractory diffuse large B cell lymphoma: Real world data
Ferhanoğlu, Burhan; Gülbaş, Zafer; Uzay, Ant; Özcan, Muhit; Özkalemkaş, Fahir; Dal, Mehmet Sinan; Kalyon, Hakan; Akay, Olga Meltem; Deveci, Burak; Bekoz, Hüseyin; Sevindik, Ömür Gökmen; Toptaş, Tayfur; Yılmaz, Asu Fergün; Koyun, Derya; Alkış, Nihan; Birtaş Ateşoğlu, Elif (American Society of Hematology, 2022)Abstract INTRODUCT ̇ION Glofitamab is a T-cell-engaging bispecific antibody connecting CD20 on B cells and CD3 on T cells. Although, most of the patients with B-cell non-Hodgkin lymphoma (BNHL) achieve complete response ... -
Nivolumab for relapsed or refractory hodgkin lymphoma experience in Turkey
Ferhanoğlu, Burhan; Beköz, Hüseyin Saffet; Karadurmuş, Nuri; Paydaş, Semra; Gülbaş, Zafer; Türker, Alev; Toptaş, Tayfur; Fıratlı Tuğlular, Tülin; Tekgündüz, Emre; Kaya, Ali Hakan; Taştemir, N.; Arat, Mutlu; Pepedil Tanrıkulu, Funda; Özkocaman, Vildan; Abalı, Hüseyin; Turgut, Mehmet; Kaynar, Leylagül; Karadoğan, İhsan; Özbalak, Murat; Özcan, Muhit; Doğu, Mehmet Hilmi; Kabukçu Hacıoğlu, Sibel; Yıldırım, Rahsan; Barışta, İbrahim; Demirkaya, Metin; Köseoğlu, Fatoş Dilan; Yüksel, Meltem Kurt; Sönmez, Mehmet; Toprak, Selami Koçak (Ferrata Storti Foundation, 2017)… -
Nivolumab for relapsed or refractory Hodgkin lymphoma: Real-life experience
Beköz, Hüseyin; Özbalak, Murat; Karadurmuş, Nuri; Paydaş, Semra; Türker, Alev; Toptaş, Tayfur; Fıratlı Tuğlular, Tülin; Altuntaş, Fevzi; Kızıl Çakar, Merih; Sönmez, Mehmet; Gülbaş, Zafer; Demir, Nazlı; Kaynar, Leylagül; Yıldırım, Rahşan; Karadoğan, İhsan; Arat, Mutlu; Kapucu, İrem; Alayvaz Aslan, Nevin; Özkocaman, Vildan; Turgut, Mehmet; Kurt Yüksel, Meltem; Özcan, Muhit; Kabukçu Hacıoğlu, Sibel; Barışta, İbrahim; Demirkaya, Metin; Saydam, Güray; Toprak, Selami Koçak; Yılmaz, Mehmet; Demirkol, Onur; Ferhanoğlu, Burhan (Springer, 2020)Classical Hodgkin lymphoma (cHL) is considered a curable disease; however, in approximately one-third of the responding patients, the disease relapses following completion of therapy. One of the drugs that have been approved ... -
Nivolumab for relapsed or refractory Hodgkin lymphoma: Real-life experience
Beköz, Hüseyin Saffet; Karadurmuş, Nuri; Paydaş, Semra; Türker, Alev; Toptaş, Tayfur; Fıratlı Tuğlular, Tülin; Sönmez, Mehmet Giray; Gülbaş, Zafer; Tekgündüz, Emre; Kaya, Ali Hakan; Özbalak, Murat; Taştemir, N; Kaynar, Leylagül; Yildirim Rahşan; Karadoğan, İhsan; Arat Ersöz, Mutlu; Pepedil Tanrıkulu, Funda; Özkocaman, Vildan; Abali, Hüseyin; Turgut, Mehmet; Kurt Yüksel, M; Özcan, Muhit; Doğu, Mehmet Hilmi; Kabukçu Hacıoğlu, Sibel; Barişta, İbrahim; Demirkaya, Metin; Köseoğlu, Fatoş Dilan; Toprak, Selami Koçak; Yilmaz, Mehmet Birhan; Demirkürek, Hüseyin; Demirkol, Mehmet Onur; Ferhanoğlu, Burhan (Oxford University Press, 2017)Background: Reed-Sternberg cells of classical Hodgkin's lymphoma (cHL) are characterized by genetic alterations at the 9p24.1 locus, leading to over-expression of programmed death-ligand 1 and 2. In a phase 1b study, ... -
Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: A real-world data from Turkey
Dal, Mehmet Sinan; Ulu, Bahar Uncu; Uzay, Ant; Akay, Olga Meltem; Beşışık, Sevgi; Yenerel, Mustafa Nuri; Çelik, Serhat; Kaynar, Leylagül; Yücel, Orhan Kemal; Deveci, Burak; Sönmez, Mehmet; Mehtap, Özgür; Beköz, Hüseyin Saffet; Sunu, Cenk; Salim, Ozan; Ulaş, Turgay; Kartı, Sami; Altuntaş, Fevzi; Ferhanoğlu, Burhan; Tuğlular, Tülin Fırat (Springer, 2023)Polatuzumab vedotin (Pola) with bendamustine and rituximab (BR) is a promising option for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). We analyzed the data of 71 R/R DLBCL patients who had ... -
Preliminary report of the academic CAR-T (ISIKOK-19) cell clinical trial in Turkey: Characterization of product and outcomes of clinical application
Erdoğan, Ebru; Yalçın, Koray; Hemşinlioğlu, Cansu; Sezgin, Aslıhan; Seyis, Utku; Kançağı, Derya Dilek; Taştan, Cihan; Yurtsever, Bulut; Turan, Raife Dilek; Çakırsoy, Didem; Abanuz, Selen; Sır Karakuş, Gözde; Elek, Muhammer; Beköz, Hüseyin Saffet; Gemici, Aliihsan; Sargın, Deniz; Arat, Mutlu; Ferhanoğlu, Burhan; Pekgüç, Ebru; Örnek, Serdar; Büyüktaş, Deram; Birgen, Nur; Ratip, Siret; Ovalı, Ercüment (Turkish Society of Hematology, 2022)Objective: Chimeric antigen receptor T (CAR-T) cell therapies have already made an impact on the treatment of B-cell malignancies. Although CAR-T cell therapies are promising, there are concerns about commercial products ...
